Oncology Department, Hospital Sirio Libanes, Faculdade de Medicina da Universisade de Sao Paulo, Sao Paulo, Brazil.
Clin Colorectal Cancer. 2013 Mar;12(1):1-7. doi: 10.1016/j.clcc.2012.06.002. Epub 2012 Jul 3.
Angiogenesis is essential to cancer development and progression, and its inhibition has been shown to benefit patients with several different malignancies. A considerable number of antiangiogenic compounds have been evaluated for the treatment of colorectal cancer, but only bevacizumab and aflibercept were able to demonstrate a survival benefit in phase III trials. In this review, we discuss important aspects of the interrelationship between tumor cells and the microenvironment leading to tumor progression, with a focus on angiogenesis. Clinical data on antiangiogenic therapies for colorectal cancer in the metastatic and adjuvant settings, as well as the potential use of antiangiogenics beyond tumor progression are analyzed. The need to identify surrogate biomarkers towards a more personalized approach in oncology is emphasized as this is becoming increasingly important in drug development.
血管生成对于癌症的发展和进展至关重要，抑制血管生成已被证明对多种不同的恶性肿瘤患者有益。已经有相当数量的抗血管生成化合物被评估用于治疗结直肠癌，但只有贝伐珠单抗和阿柏西普在 III 期临床试验中显示出了生存获益。在这篇综述中，我们讨论了导致肿瘤进展的肿瘤细胞与微环境之间相互关系的重要方面，重点是血管生成。分析了转移性和辅助治疗结直肠癌的抗血管生成治疗的临床数据，以及抗血管生成药物在肿瘤进展之外的潜在用途。强调了需要确定替代生物标志物以实现肿瘤学的更个性化方法，因为这在药物开发中变得越来越重要。
